The Pancreatic Cancer Collective

Passion and commitment coming together to innovate
and accelerate pancreatic cancer research.

Overview

We are delighted to be partnering with our friends at Stand Up To Cancer on this exciting new initiative to improve outcomes for pancreatic cancer patients. The Pancreatic Cancer Collective will accelerate research for pancreatic cancer patients who desperately need better treatments.

Through the Collective, we will

  • Inspire collaboration among people who haven’t worked together
  • Spread funding to new centers
  • Leverage artificial intelligence approaches
  • Find new treatments for pancreatic cancer
  • Utilize the breadth and expertise of existing Stand Up To Cancer – Lustgarten teams and researchers

 

History

Since 2012, the Lustgarten Foundation and Stand Up To Cancer have funded more than 170 investigators across 28 leading research centers in both the United States and United Kingdom. These efforts include four Dream Teams and five Research Teams, including two Convergence Teams bringing together computational experts with clinical oncologists. Cancer Interception, research supporting the earliest diagnosis of pancreatic cancer, is the focus of one of the Dream Teams and one of the Research Teams. All told, these collaborative teams have planned, started or completed 22 clinical trials. The Pancreatic Cancer Collective will build on this momentum and push the boundaries of what can be accomplished even further.

The Pancreatic Cancer Collective is an initiative of the Lustgarten Foundation and Stand Up To Cancer to improve pancreatic cancer patient outcomes. Together, these leading cancer research organizations will attract new collaborators; improve diagnosis of pancreatic cancer using big data; find new treatments for pancreatic cancer; and support the next generation of pancreatic cancer investigators. Engaging thought leaders, researchers, institutions, and companies, the Collective will innovate and accelerate research on the edge of science.

Request for Applications

Requests for applications (RFA’s) will be issued on April 30 to support pre-clinical development research seeking to increase the number of innovative and effective therapies to treat pancreatic cancer.